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A decrease in renal synthesis of nitric oxide (NO) in the
progression of diabetic nephropathy has been documented.
As (6R)-5,6,7,8-tetrahydrobiopterin (BH4) is an essential
cofactor of NO synthase, we investigated whether BH4
deficiency is involved in the pathogenesis of nephropathy.
Ten-week-old Otsuka Long–Evans Tokushima Fatty (OLETF)
rats were used as a type II diabetic model, and Long–Evans
Tokushima Otsuka (LETO) rats as the healthy controls. OLETF
rats were orally treated with BH4 (10 mg/kg daily) or with
water from 10 to 61 weeks of age. In another experiment,
OLETF rats were treated orally with a calcium channel
blocker, benidipine (5 mg/kg daily), or with 0.3%
carboxymethyl cellulose (nontreated) from 10 to 52 weeks of
age. Proteinuria was observed periodically, and at the end of
the study, BH4 level and GTP cyclohydrolase I (GTPCH) activity
in the kidney were measured. Proteinuria was observed at 13
weeks of age in the OLETF rats, and deteriorated until 61
weeks of age. Supplemental BH4 reduced the proteinuria.
At 52 weeks of age, GTPCH activity and the BH4 level were
decreased in the plasma and kidneys of OLETF rats, whereas
they were significantly higher in the benidipine group than in
the nontreated group. Proteinuria was milder in the
benidipine group than in the nontreated group, without a
concomitant decrease in blood pressure. Histologically
observed glomerulosclerosis was mild in the BH4 and
benidipine groups. In type II diabetic rats, renal BH4 is
considered to play a crucial role in the pathogenesis of
diabetic nephropathy. Benidipine was found to preserve BH4
levels, suggesting therapeutic renoprotective effects.
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Nitric oxide (NO) is an important regulator of renal
function, including renal microcirculation, renal nerve
activity, and tubular reabsorption of fluids and electrolytes.1,2
Although there have been confusing and controversial data
regarding whether NO production is beneficial for protection
of the kidney in diabetes, a strong body of evidence has
supported the contention that, in the diabetic kidney, NO
synthesis is decreased,3,4 and disorder of NO production is an
important cause of nephropathy.5 However, the mechanism
of impaired NO production in diabetic nephropathy is not
fully understood.
In the synthetic pathway of NO, (6R)-5,6,7,8-tetrahydro-
biopterin (BH4) is an important allosteric effector of NO
synthase (NOS) through stabilization of the dimer, an active
form of NOS.6,7 When BH4 is severely decreased, NOS does
not synthesize NO but rather O2
.8 In fact, a decrease in BH4
has been reported in the aorta of rats fed with high fructose
(a model of insulin resistance),9 and cultured endothelial cells
isolated from BioBreeding rats (a model of spontaneous type
I diabetes).10 In these studies, a decrease in the activity of
GTP cyclohydrolase I (GTPCH), a key enzyme of BH4
synthesis, was suggested to be the cause of the BH4 decrease.
However, whether BH4 is decreased in diabetic nephropathy
and to what extent any decrease is involved in the progress of
nephropathy are still unclear.
In clinical practice, the progress of diabetic nephropathy is
effectively suppressed by blood pressure control with
antihypertensive drugs. The blood pressure control per se is
thus considered important to prevent macro- and micro-
angiopathy in diabetes.11,12 However, it may also be true that
inhibition of the renin–angiotensin system yields a renopro-
tective effect on chronic kidney disease, in addition to blood
pressure reduction. The mechanism of this potential effect is
at least one part owing to improvement in glomerular
hypertension.13 In addition to this effect, inhibitors of the
renin–angiotensin system have been suggested to have
protective endothelial function and to increase NO synthe-
sis.14 Similar to inhibitors of the renin–angiotensin system,
calcium channel blockers (CCBs) have also been demons-
trated to enhance NOS in endothelial cells.15 Furthermore,
benidipine, a long-acting CCB, increases the level of mRNA
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transcript of endothelial NOS in the left ventricular
endothelial cells of hypertensive rats16 and elevates the level
of NO in the ischemic heart of dogs.17 In our preliminary
study, we found a decrease in the plasma level of BH4
(a deficiency in BH4) in spontaneous type II diabetic rats
with nephropathy. Upon discovery of this deficiency, we
further examined to what extent the deficiency is involved in
the etiology of nephropathy. To this end, the effect of
supplementation with BH4 was examined, and whether
administration of the CCB, benidipine, is effective for
suppression of proteinuria and prevention of BH4 deficiency
in this rat model.
RESULTS
Changes in body weight, plasma glucose, and blood pressure
Table 1 shows the changes in body weight, plasma glucose,
and blood pressure measured in 13-, 37-, and 61-week-old
rats in protocol 1. On all occasions, the nontreated Otsuka
Long–Evans Tokushima Fatty (OLETF) group and the BH4-
treated OLETF group weighed more than the control
Long–Evans Tokushima Otsuka (LETO) group. Plasma
glucose concentration in the nontreated OLETF group and
the BH4-treated OLETF group was significantly higher than
that in the LETO group throughout the study period. Systolic
blood pressure was the same between the nontreated OLETF
group and the BH4-treated group, both showing significantly
higher levels than in the LETO group. Altogether, BH4 had no
effect on body weight, plasma glucose, or blood pressure in
this diabetic rat model.
Table 2 shows the changes in body weight, plasma glucose,
and blood pressure in protocol 2. Similar to the results in
protocol 1, the nontreated OLETF group showed significantly
higher levels of body weight, plasma glucose, and systolic
blood pressure than those in the LETO group, and the
treatment with benidipine resulted in no change in any of
these parameters.
Changes in urinary protein excretion
Urinary protein excretion increased with age in the
nontreated OLETF group, but not in the LETO group
(Figure 1). In contrast, at 37 and 61 weeks of age, urinary
protein excretion was significantly lower in the BH4-treated
OLETF group, indicating the amelioration of proteinuria.
The effect of benidipine on urinary protein excretion is
shown in Figure 2. Benidipine-induced reduction in urinary
protein excretion was significant from 28 weeks until the end
of the study (52 weeks).
Creatinine clearance
No significant difference in creatinine clearance (CCr) was
observed between the OLETF rats and BH4-treated OLETF
rats (4.872.6 and 3.872.0 ml/min/kg body weight,
mean7s.d., respectively, P¼ 0.5759, one-way analysis of
variance (ANOVA)). CCr in the LETO rats was 4.072.1
(mean7s.d.). Thus, a decrease in CCr in diabetic nephro-
pathy was not observed.
Table 1 | Changes in body weight, plasma glucose, and blood
pressure during the BH4 supplementation study
Rats 13 weeks 37 weeks 61 weeks
Body weight (g) LETO 360728 518728 579740
OLETF 468747* 711741* 759752*
BH4 456731* 688734* 740735*
Plasma glucose (mg/dl) LETO 209732 184728 190730
OLETF 298764* 243741* 247729*
BH4 284748* 250750* 250750*
Blood pressure (mm Hg) LETO 11976 11477 114713
OLETF 13676* 13879* 135710*
BH4 13079* 139714* 143712*
LETO, Long–Evans Tokushima Otsuka rats (controls) (n=12); OLETF, Otsuka Long–-
Evans Tokushima Fatty rats that were untreated (n=11); BH4, OLETF rats treated with
BH4 (n=9).
Data represent mean7s.d.
*Po0.01 compared with LETO rats of the same age.
Table 2 | Changes in body weight, plasma glucose, and blood
pressure during the benidipine treatment study
Rats 16 weeks 28 weeks 40 weeks 52 weeks
Body LETO 384726 478729 519732 539735
weight (g) OLETF 495722* 650737* 701746* 694754*
Benidipine 472721* 609740* 655745* 650744*
Plasma LETO 198713 187726 191724 179716
glucose OLETF 281732* 287732* 282742* 263736*
(mg/dl) Benidipine 259722* 272751* 252745* 245748*
Blood LETO 12678 11579 114710 118711
pressure OLETF 148714* 13676* 14178* 145716*
(mm Hg) Benidipine 142713* 13379* 135720* 14278*
LETO, Long–Evans Tokushima Otsuka rats (controls) (n=12); OLETF, Otsuka Long–-
Evans Tokushima Fatty rats that were untreated (n=10); benidipine, OLETF rats
treated with benidipine (n=8).
Data represent mean7s.d.
*Po0.01 compared with LETO rats of the same age.
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Figure 1 | Changes in urinary protein excretion in the three
groups of rats. Data represent mean7s.d. Closed bars are for
LETO rats (n¼ 12), open bars are for untreated OLETF rats (n¼ 11),
and stippled bars are for the OLETF rats treated with BH4 (n¼ 9).
*Po0.05 compared with LETO rats. #Po0.05 compared with
OLETF rats.
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Similarly, in protocol 2, no significant difference in CCr
was observed between the OLETF rats and BH4-treated
OLETF rats (3.870.9 and 3.970.8 ml/min/kg body weight,
mean7s.d., respectively, P¼ 0.4621, ANOVA). CCr in the
LETO rats was 4.270.7 (mean7s.d.). Thus, again no
decrease in CCr in diabetic nephropathy was observed.
Histologic examination
The histopathological features of the kidneys of the LETO
rats, OLETF rats, BH4-treated OLETF rats (protocol 1), and
benidipine-treated OLETF rats (protocol 2) are summarized
in Figure 3 and Table 3. Glomerulosclerosis was not seen in
the LETO rats, but was evident in both untreated and BH4-
treated OLETF rats (as shown in Table 3). Data were obtained
from examination of 12378 glomeruli of each of the
untreated OLETF rats (n¼ 6) and of 12377 glomeruli of
each of the BH4-treated rats (n¼ 6). The glomerular sclerosis
index of BH4-treated rats was less than that of the untreated
rats. As shown in Figure 3c, glomerulosclerosis in BH4-
treated rat kidney was milder than that in untreated OLETF
rat kidney (Figure 3b).
To evaluate glomerulosclerosis in protocol 2, we examined
11475 glomeruli of each of the untreated OLETF rats
(n¼ 6) and 135710 glomeruli of each of the benidipine-
treated OLETF rats (n¼ 6). The glomerular sclerosis index of
the benidipine-treated rats was less than that of the untreated
rats (Table 3). The glomerulosclerosis in the benidipine-
treated rat kidney (Figure 3d) was milder than that in
the untreated OLETF rat kidney (Figure 3b) (as shown
in Figure 3).
Measurement of plasma and kidney biopterins
Table 4 shows the amounts of total forms of biopterin and
BH4 in the plasma and kidneys, as well as the GTPCH
activities in the kidneys. Both total forms of biopterin and
BH4 levels were lower in the plasma and kidneys of the
nontreated OLETF group than in the LETO group. In
contrast, the amounts of biopterins and BH4 were greater in
both the plasma and kidneys in the benidipine-treated
OLETF group, indicating a recovery of these biopterins by the
treatment with benidipine. The BH4/biopterin ratio indicates
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Figure 2 | Changes in urinary protein excretion in the three
groups of rats. Data represent mean7s.d. Closed bars are for LETO
rats (n¼ 12), open bars are for untreated OLETF rats (n¼ 10), and
stippled bars are for the OLETF rats treated with benidipine (n¼ 8).
*Po0.05 compared with LETO rats. #Po0.05 compared with OLETF
rats.
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Figure 3 | Light microscopic observation of kidneys. Photographs
specifically focused on the glomerulus. (a) LETO at 61 weeks old.
(b) OLETF at 61 weeks old. (c) BH4-treated OLETF at 61 weeks old.
(d) Benidipine-treated OLETF at 52 weeks old. In (b), enlarged
glomerulus and developed nodular diabetic nodules are evident.
Table 3 | The glomerular sclerosis index of OLETF rats and
those treated with BH4 and benidipine
OLETF BH4 P-value
Glomerular sclerosis index 65.2724.8 34.8715.2 0.0306
OLETF Benidipine P-value
Glomerular sclerosis index 55.0712.4 27.7714.3 0.0104
OLETF, Otsuka Long–Evans Tokushima Fatty rats that were untreated (n=6); BH4,
OLETF rats treated with BH4 (n=6); benidipine, OLETF rats treated with benidipine
(n=6).
P-values were analyzed by Mann–Whitney U-test.
Data represent mean7s.d.
Table 4 | Tissue content of biopterin and tetrahydrobiopterin,
and GTP cyclohydrolase I activity
LETO OLETF Benidipine
Plasma
Biop (pmol/ml) 13771 8571* 9971*,#
BH4 (pmol/ml) 11172 4471* 7671*
,#
BH4/Biop 0.8170.01 0.5170.004* 0.7770.009*
,#
Kidney
Biop (pmol/g tissue) 32775 20972* 25172*,#
BH4 (pmol/g tissue) 26774 13672* 20475*
,#
BH4/Biop 0.8270.003 0.6570.01* 0.8170.02
#
GTPCH (U/mg protein) 0.9970.01 0.5870.01* 0.7470.01*,#
LETO, Long–Evans Tokushima Otsuka rats (controls) (n=12); OLETF, Otsuka Long–-
Evans Tokushima Fatty rats that were untreated (n=10); benidipine, OLETF rats
treated with benidipine (n=8); Biop, amount of total forms of biopterin; BH4,
tetrahydrobiopterin; GTPCH, GTP cyclohydrolase I activity. BH4/Biop indicates the
activity of dihydropteridine reductase.
Data represent mean7s.d.
*Po0.01 compared with LETO rats.
#Po0.01 compared with OLETF rats.
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the activity of dihydropteridine reductase, the recycling
enzyme that produces BH4 from BH2. Both in the plasma
and kidney, the ratio of BH4/biopterin was decreased in the
nontreated OLETF rats in comparison with that in the LETO
rats. However, the ratio was maintained in the benidipine-
treated OLETF rats. Thus, the scavenging activity by BH4 in
the OLETF rats was likely recovered by treatment with
benidipine. The GTPCH activity in the kidneys was lower in
the nontreated OLETF rats than the LETO rats, but was
recovered by benidipine.
DISCUSSION
Diabetic nephropathy in OLETF rats is characterized by
typical renal lesions such as proteinuria, hyper-
trophy, glomerular sclerosis, and microangiopathy.18
The development of nephropathy in the OLETF rats in
the present study was evidenced by severe proteinuria
and glomerulosclerosis, with concomitant decreases in BH4
and the activity of GTPCH. BH4 supplementation retarded
nephropathy. Thus, BH4 and GTPCH may be involved in the
pathogenesis of nephropathy in this diabetic model. In
addition, we found that benidipine slowed the progression of
nephropathy and impeded the decrease in BH4 and GTPCH
activity.
Although BH4 and benidipine reduced proteinuria and
glomerulosclerosis in these diabetic rats, CCr in the OLETF
rats with the treatments did not differ from that in the
control OLETF rats. One possible explanation is that the
normal level of CCr in the OLETF rats was not affected by
these treatments. However, a more likely explanation is that
BH4 and benidipine were more effective in ameliorating
morphological changes in this diabetic model (as shown in
Figure 3 and Table 3).
The majority of evidence has indicated a beneficial effect
of NO in maintaining renal function.19 However, NO rapidly
reacts with superoxide to form toxic peroxynitrite, and thus
peroxynitrite has been considered a crucial factor in
deteriorating renal function. This oxidative–nitrosative stress
increases and causes diabetic complications.20 This idea was
recently supported by Chander et al.,21 who demonstrated
the therapeutic effect of a peroxynitrite scavenger, ebselen, in
Zucker diabetic rats. The present results support the idea that
the BH4 depletion and dysregulation of NOS are critically
involved in the pathogenesis of diabetic nephropathy.
In diabetics, impaired endothelium-dependent vasodila-
tion has been considered to be the result of disorder of the
NO system.22 In in vitro studies, BH4 added to bathing
solution ameliorated the endothelium-dependent relaxation
of isolated vascular rings from diabetic rats.23 Moreover,
impairment of endothelium-dependent relaxation of the
aortic strips from fructose-fed rats (insulin-resistant rats) was
restored by oral supplementation of BH4.
24 A decrease in BH4
has been demonstrated in the aorta of insulin-resistant
rats9,24 and in the brain of type I diabetic rats,25 where the
NO system is known to be impaired. In the kidney, the
activity of NOS decreases in the renal cortex of diabetic obese
Zucker rats.26 Chronic NOS inhibition is shown to induce
renal structural and functional damage in diabetic nephro-
pathy.27,28 In the present study, the renal content of BH4 in
OLETF rats at 52 weeks of age was about 50% of that in the
healthy control LETO rats at the same age. Taking the
biological pathway of NO synthesis into account, a strong
contention can be made that, in diabetic kidney, a deficiency
in BH4 results in impaired NO synthesis. Impaired NO
synthesis is thus a potential factor of deterioration in diabetic
nephropathy.
The activities of GTPCH and dihydropteridine reductase
are low in insulin-resistant rats.9,24 Consistently, we found in
type II diabetic kidney that these two enzyme activities and
the content of BH4 were lower than in healthy controls. As
has been understood, a decrease in GTPCH causes a decrease
in BH4. In the situation that BH4 is depleted, NOS produces
superoxide anion instead of NO.29,30 The superoxide anion
decreases the half-life of NO and is also active in forming
peroxynitrite. The level of BH4 depends on the cellular redox
state; the superoxide anion inhibits the change from BH2
(oxidized form of BH4) to BH4 by suppression of
dihydropteridine reductase.31 The oxidative stress (increase
in the superoxide) further decreases the BH4 level and half-
life of NO. This vicious cycle appears to occur in diabetics
and to cause systemic organ damage, including in the kidney.
It is not clear why GTPCH activity was low in the present
disease model. However, insulin activates both GTPCH and
dihydropteridine reductase, and stimulates BH4 synthesis.
32
As the diabetic rats used in the present study have
hyperinsulinemia and insulin resistance,18 the insulin-resis-
tant state may have caused the decrease in the activity of
GTPCH.
In the present study, benidipine impeded the decrease in
both GTPCH activity and the BH4 level in the kidney. As
noted above, why GTPCH activity decreased in the diabetic
kidney is unclear, and hence the mechanism of the effect of
benidipine is likewise unclear. The apparent restoration of
BH4 by benidipine might be an indirect effect, as the
therapeutic effect of CCBs on type II diabetic nephropathy
has been documented, mostly through improvement in
hemodynamics. Moreover, if CCBs are effective in improving
insulin resistance, this may explain, at least in part, the
mechanism of action of benidipine. Another possibility is
that benidipine might activate GTPCH by increasing
intracellular Ca in the endothelium, particularly in the
glomerular capillaries. Although there is no direct evidence to
prove this theory, the following reports support this idea.
GTPCH has been shown to be activated by intracellular
influx of Ca.33 Nitrendipine has been reported to increase
intracellular Ca in aortic endothelial cells in culture.34
Another CCB, felodipine, has been shown to increase
endothelial NOS protein mass and nitrate/nitrite generation
in rat aortic endothelial cells in culture.15 In addition, CCBs
have been demonstrated to enhance NO availability in the
human forearm vascular bed,35 canine coronary micro-
vessels,36 and rabbit endothelial cells.37
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In the present study, benidipine at a dose of 5 mg/kg did
not induce a statistically significant decrease in blood
pressure in the diabetic OLETF rats during the observation
period from 28 to 52 weeks. In contrast, Jesmin et al.38
reported a significant but minor decrease in blood pressure
by oral administration of benidipine (3 mg/kg) to OLETF
rats. In clinical cases, when blood pressure is not too high in
patients with type II diabetes and nephropathy, the blood
pressure-lowering effect of antihypertensive drugs is not
always prominent, even if the drugs are effective for
renoprotection.39,40 In other rats, the blood pressure decrease
by benidipine was less when the basal pressure was not very
high.41 The blood pressure of the OLETF rats that we used
ranged between 135 and 145 mm Hg, whereas that of the
LETO rats ranged between 114 and 119 mm Hg on average,
indicating a mild hypertensive state in this disease model.
Thus, our results indicate that the effect of benidipine to
decrease urinary excretion of protein is independent of any
antihypertensive effect.
In conclusion, the renal BH4 level was found to be
decreased in the type II diabetic rat model. The decreased
level of renal BH4 is attributable to the decrease in the activity
of GTPCH in the kidney. The deficiency in BH4 is considered
to play a crucial role in the pathogenesis of diabetic
nephropathy, probably through impairment of NO synthesis
in the kidney. Treatment with benidipine was effective in
reducing urinary protein excretion, and maintained renal
GTPCH activity and BH4 levels without affecting blood
pressure. This drug is thus considered effective for renopro-
tection in this model.
MATERIALS AND METHODS
Animals
All procedures were in accordance with our institutional ethical
guidelines for animal research. We used spontaneous type II diabetic
OLETF rats, and related non-diabetic LETO rats as the healthy
controls. Male OLETF and LETO rats were maintained at the animal
laboratory of Osaka City General Hospital. All rats were kept in a
specific pathogen-free facility with controlled temperature
(23721C) and humidity (5575%) with 12-h cycles of light and
dark. They were fed standard laboratory chow (CE-2, CLEA Japan
Inc., Tokyo, Japan), and tap water was available ad libitum.
Experimental design
Protocol 1 (BH4-supplement study). We prepared three groups
of rats: LETO as the control (n¼ 12), OLETF as the nontreated
diabetic rats (n¼ 11), and OLETF (n¼ 9) treated with sapropterin
hydrochloride (BH4) at a daily dose of 10 mg/kg. BH4 was dissolved
in water (5 mg/ml) and was administered to the BH4-treated OLETF
rats by gastric gavage once a day, starting when the rats were 10
weeks old. The control LETO and the nontreated OLETF rats
received water (2 ml/kg) by the same route.
Body weight, systolic blood pressure, and plasma glucose
concentration were measured when the rats were 13, 37, or 61
weeks old. At these times, the rats were transferred to metabolic
cages, and urine was collected for 24 h at 41C. Blood was sampled
from a tail vein.
Protocol 2 (benidipine treatment study). We prepared three
groups of rats: LETO as the control (n¼ 12), a group of nontreated
OLETF (n¼ 10), and a group of OLETF treated with benidipine
hydrochloride, at a daily dose of 5 mg/kg (n¼ 9). Benidipine
hydrochloride was suspended in 0.3% carboxymethyl cellulose
solution at a concentration of 2.5 mg/ml. The benidipine suspension
was administered to benidipine-treated OLETF by the same route as
in protocol 1. Both LETO and nontreated OLETF rats received 0.3%
carboxymethyl cellulose solution at a daily dose of 2 ml/kg. When
the rats were 16, 28, 40, and 52 weeks old, we examined the same
parameters as in protocol 1. At 52 weeks of age, the study was
stopped and the rats were killed by intraperitoneal injection of
pentobarbital. Blood and kidneys were then obtained to determine
the biopterin level and GTPCH activity.
Analysis
Urinary protein was measured by the pyrogallol red method. Plasma
glucose was measured using a modified hexokinase method. CCr
was calculated using a standard formula at the end of the study
period with urine collected over a 24-h period. BH4 and each
biopterin form were measured using high-performance liquid
chromatography as described elsewhere,9,42 and the amount of
BH4 was estimated from a difference between the total of all the
biopterin forms (BH4, BH2, and oxidized biopterin) and alkaline-
stable biopterin (BH2 and oxidized biopterin). GTPCH activity was
assayed using high-performance liquid chromatography to measure
neopterin, which was generated from dihydroneopterin tripho-
sphate after oxidation and phosphatase treatment.24,42
Measurement of blood pressure
Systolic blood pressure was periodically measured using an
electrosphygmomanometer (PS-200A, Riken Kaihatsu, Tokyo,
Japan) soon after the day of urine collection. At least three blood
pressure readings of each rat were taken over a short period.
Histologic examination
Kidneys were fixed in phosphate-buffered 4% formaldehyde and
embedded in paraffin, and sections 2–3 mm thick were stained with
periodic acid-Schiff. All preparations were evaluated by our
investigators who had no prior knowledge of the rat groupings. To
quantify glomerulosclerosis, the glomerular sclerosis index was used
as described previously.43,44 Individual glomeruli were examined,
and the severity of glomerulosclerosis was graded from 0 to 4 to
express the percentage that the glomerulus in question was affected.
Injury scores were then calculated by multiplication of these grades
for individual glomeruli by the percentage of glomeruli with the
same extent of injury. The extent of injury in each tissue specimen
was then obtained by the addition of these injury scores.
Statistical analysis
Data are expressed as the mean7s.d. All differences between groups
were analyzed by ANOVA followed by Scheffe’s method (StatView
version 5.0), except as noted in ‘Histologic results’. Differences were
considered to be statistically significant when Po0.05.
Materials
LETO and OLETF rats were obtained from the Tokushima Research
Institute of Otsuka Pharmaceutical Co. (Tokushima, Japan). BH4
was a kind gift from Suntory Ltd (Osaka, Japan). Benidipine was
kindly donated by Kyowa Hakko Co. Ltd (Tokyo, Japan).
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